# Tonix Pharmaceuticals Holding Corp.: overview TNXP · Nasdaq · CIK 1430306 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tnxp.md) · [Financials](/companies/tnxp/financials.md) · [Filings](/companies/tnxp/filings.md) · [Insiders](/companies/tnxp/insiders.md) Latest reported revenue: [$13.5m](/filings/0001999371-26-017452.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001999371-26-017452). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.8](/filings/0001999371-25-017370.md) | [2.6 d](/filings/0001999371-26-005730.md) | [2.4](/filings/0001999371-26-010486.md) | [2.0](/filings/0001999371-26-017452.md) | [3.3](/filings/0001999371-25-017370.md) | [5.4 d](/filings/0001999371-26-005730.md) | [6.9](/filings/0001999371-26-010486.md) | [13.5](/filings/0001999371-26-017452.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(551.2%)](/filings/0001999371-25-017370.md) | [(870.6%) d](/filings/0001999371-26-005730.md) | [(660.9%)](/filings/0001999371-26-010486.md) | [(1416.2%)](/filings/0001999371-26-017452.md) | [(1005.1%)](/filings/0001999371-25-017370.md) | [(895.8%) d](/filings/0001999371-26-005730.md) | [(603.9%)](/filings/0001999371-26-010486.md) | [(314.1%)](/filings/0001999371-26-017452.md) | | Net margin | % | [(503.6%)](/filings/0001999371-25-017370.md) | [(856.2%) d](/filings/0001999371-26-005730.md) | [(692.8%)](/filings/0001999371-26-017452.md) | [(1415.0%)](/filings/0001999371-26-017452.md) | [(972.9%)](/filings/0001999371-25-017370.md) | [(870.3%) d](/filings/0001999371-26-005730.md) | [(584.4%)](/filings/0001999371-26-017452.md) | [(299.4%)](/filings/0001999371-26-017452.md) | | Diluted EPS | $ per share | [(22.68)](/filings/0001999371-25-017370.md) | not reported | [(2.84)](/filings/0001999371-26-010486.md) | [(3.86)](/filings/0001999371-26-017452.md) | [(3.59)](/filings/0001999371-25-017370.md) | not reported | [(2.93)](/filings/0001999371-26-010486.md) | [(2.44)](/filings/0001999371-26-017452.md) | | Free cash flow | $m | [(18.8) d](/filings/0001999371-25-017370.md) | [(14.6) d](/filings/0001999371-26-005730.md) | [(16.6)](/filings/0001999371-26-010486.md) | [(15.4) d](/filings/0001999371-26-017452.md) | [(29.7) d](/filings/0001999371-25-017370.md) | [(41.5) d](/filings/0001999371-26-005730.md) | [(44.0)](/filings/0001999371-26-010486.md) | [(42.8) d](/filings/0001999371-26-017452.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [7.8](/filings/0001999371-25-002786.md) | [10.1](/filings/0001999371-26-005730.md) | [13.1](/filings/0001999371-26-005730.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(1523.9%)](/filings/0001999371-25-002786.md) | [(1354.3%)](/filings/0001999371-26-005730.md) | [(959.1%)](/filings/0001999371-26-005730.md) | | Net margin | % | not reported | not reported | [(1501.8%)](/filings/0001999371-25-002786.md) | [(1288.3%)](/filings/0001999371-26-005730.md) | [(946.2%)](/filings/0001999371-26-005730.md) | | Diluted EPS | $ per share | [(8.10)](/filings/0001387131-23-003377.md) | [(20.01)](/filings/0001999371-24-004297.md) | [(14720.25)](/filings/0001999371-25-002786.md) | [(176.60)](/filings/0001999371-26-005730.md) | [(14.57)](/filings/0001999371-26-005730.md) | | Free cash flow | $m | [(111)](/filings/0001387131-23-003377.md) | [(146)](/filings/0001999371-24-004297.md) | [(110)](/filings/0001999371-25-002786.md) | [(61.0)](/filings/0001999371-26-005730.md) | [(103)](/filings/0001999371-26-005730.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tnxp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $17.8m | 1,398,041 | | Added +429,864 | | [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $14.9m | 1,166,752 | | Added +1,041,338 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $12.3m | 966,932 | | Added +747,259 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $11.3m | 882,595 | | Added +721,387 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.8m | 691,895 | | Added +173,245 | | [Jones Hill Capital LP](/funds/2102314.md) | 2026-06-30 | $8.0m | 625,428 | | Added +173,312 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $5.0m | 395,260 | | Added +81,969 | | [Ishara Investments LP](/funds/2111609.md) | 2026-06-30 | $4.3m | 338,250 | | New +338,250 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.5m | 271,374 | | Added +40,767 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $3.0m | 231,682 | | Added +4 | ## Recent filings [All 1,508 filings](/companies/tnxp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 11:00 ET | [8-K](/filings/0001493152-26-047139.md) | 2.02 Results of operations; 8.01 Other events | 0001493152-26-047139 | | 2026-10-02 | 21:20 ET | [8-K](/filings/0001493152-26-045603.md) | 8.01 Other events | 0001493152-26-045603 | | 2026-09-22 | 11:05 ET | [8-K](/filings/0001493152-26-043644.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-043644 | | 2026-09-08 | 11:05 ET | [8-K](/filings/0001493152-26-041689.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-041689 | | 2026-08-18 | 20:00 ET | [8-K](/filings/0001493152-26-039000.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001493152-26-039000 | | 2026-08-10 | 12:09 ET | [10-Q](/filings/0001999371-26-017452.md) | Quarterly report, period 2026-06-30 | 0001999371-26-017452 | | 2026-08-10 | 11:15 ET | [8-K](/filings/0001493152-26-036740.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-036740 | | 2026-08-03 | 11:05 ET | [8-K](/filings/0001493152-26-035741.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-035741 | | 2026-07-21 | 20:05 ET | [8-K](/filings/0001493152-26-034079.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-034079 | | 2026-07-13 | 11:05 ET | [8-K](/filings/0001493152-26-032925.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-032925 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001999371-26-005730.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1430306 - Tickers: TNXP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.